An overview of integration

Set is China's bedside and bedside cytopathic therapy company, jointly established by 2359.HK and JunoTherapeutics, to develop a breakthrough cellular immune assay associated with hematological cancer and physical tumors. The core waiting product of the collection is Relma-cel, and the relevant new application was granted by the State Administration of Supervision and Supervision in September this year, which is expected to be China's first approval of CAR-T for first-class biological products.

Negative factor

The market is still a biotech company that is still in bed. It has a limited history and has not yet made any profit from the sale of cytopathic acid products. Since its inception, it has generated a lot of money, and it is expected that it will continue to do so in the future. It is also intended to assess future profitability.